Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ISOLYTE P with 5% Dextrose provides electrolyte replacement and caloric supplementation. Dextrose is metabolized to carbon dioxide and water, yielding energy. Electrolytes are essential for maintaining osmotic balance, acid-base equilibrium, and normal cellular function.
Isolyte H in Dextrose 5% provides a balanced electrolyte solution with glucose to maintain fluid and electrolyte homeostasis. Dextrose is metabolized to carbon dioxide and water, providing calories. Electrolytes replenish losses and maintain acid-base balance.
Source of calories and electrolytes in patients requiring IV fluids,Maintenance or replacement of fluid and electrolyte losses in pediatric patients,Treatment of dehydration,Hypokalemia prevention or treatment
Fluid and electrolyte replacement,Maintenance of hydration and electrolyte balance in patients unable to tolerate oral intake,Correction of hypovolemia,Mild to moderate metabolic acidosis
Intravenous infusion. Adult dose: 1000-2000 m L over 24 hours, adjusted based on fluid and electrolyte needs. Typical rate: 125-150 m L/hour.
Intravenous infusion; rate determined by clinical condition, electrolyte requirements, and fluid balance. Typical adult maintenance: 100-200 m L/hour. Maximum infusion rate: 1000 m L/hour.
Dextrose: rapid clearance, half-life ~1.5-2 hours in normoglycemic patients; prolonged in renal impairment or diabetes. Electrolytes follow homeostatic regulation with no defined terminal half-life.
Not applicable as a fixed drug. Electrolytes have no defined half-life; dextrose is rapidly cleared with a metabolic half-life of approximately 5-10 minutes due to insulin-mediated uptake.
Dextrose is metabolized via glycolysis and the Krebs cycle. Electrolytes are not metabolized but are excreted or reabsorbed.
Dextrose is metabolized via glycolysis and the citric acid cycle to carbon dioxide and water, primarily in the liver; insulin promotes cellular uptake. Electrolytes are not metabolized but are excreted or reabsorbed by the kidneys.
Renal excretion of free water and electrolytes; dextrose is metabolized to CO2 and water, with negligible biliary or fecal elimination. Approximately 50-70% of infused water is excreted renally within 24 hours, adjusted by ADH and renal function.
Electrolytes and dextrose are primarily excreted renally. Potassium, sodium, chloride, and magnesium are eliminated via kidneys. Dextrose is metabolized to CO2 and water, with negligible renal excretion. Biliary/fecal elimination is minimal (<5%).
Dextrose: negligible (<1%). Electrolytes: sodium and potassium are not protein bound; chloride, acetate, and gluconate are free in plasma.
Negligible for electrolytes and dextrose (<5%).
Dextrose: ~0.2 L/kg (limited to extracellular fluid initially); electrolytes distribute according to body water compartments: sodium ~0.2 L/kg (ECF), potassium ~0.4 L/kg (ICF).
Not applicable as a single compound. Electrolytes distribute primarily in extracellular fluid (0.2 L/kg for sodium), total body water (0.6 L/kg for water). Dextrose distributes in total body water (0.55 L/kg).
Intravenous: 100% (complete bioavailability). No oral formulation; oral dextrose has variable absorption.
Intravenous: 100%.
GFR 10-50 m L/min: Monitor electrolytes closely; reduce infusion rate if hyperkalemia or fluid overload. GFR <10 m L/min: Contraindicated if severe renal impairment with oliguria or anuria; use with caution and adjust volume based on residual renal function.
No specific dose adjustment required; monitor serum electrolytes and fluid status in renal impairment due to risk of hyperkalemia, hypernatremia, or fluid overload.
Child-Pugh A: No adjustment. Child-Pugh B and C: Monitor for fluid retention and electrolyte imbalances; adjust volume and rate accordingly.
No specific dose adjustment; use with caution in severe hepatic impairment due to potential for fluid and electrolyte disturbances.
Weight-based: 20-100 m L/kg/day, adjusted for hydration status and maintenance needs. Maximum rate: 4-8 m L/kg/hour depending on age and clinical condition.
Weight-based: 2-6 m L/kg/hour or as per Holliday-Segar method for maintenance; monitor serum electrolytes closely.
Elderly patients: Use lower end of dose range due to decreased renal function and risk of fluid overload; monitor electrolytes and volume status closely.
Use with caution; consider lower initial rates due to reduced renal function and increased risk of fluid overload; monitor electrolytes and volume status.
None
None for this product; however, caution is required in patients with congestive heart failure, renal impairment, or conditions predisposing to electrolyte imbalances.
Risk of hyperglycemia, especially in patients with diabetes mellitus,Monitor serum electrolytes, glucose, and fluid balance,May cause fluid overload in patients with renal or cardiac impairment,In neonates, rapid administration may cause hyperinsulinemia and rebound hypoglycemia,Use with caution in patients with severe electrolyte disturbances
Risk of fluid overload in patients with compromised cardiac or renal function,Risk of electrolyte imbalances (hyperkalemia, hyponatremia, hypernatremia),Administration may cause phlebitis or thrombosis,Monitor serum electrolytes, glucose, and fluid balance,Use with caution in patients with diabetes or glucose intolerance,Not for use when hyperosmolality is present
Hyperglycemia,Hypernatremia,Hypersensitivity to any component,Severe dehydration with electrolyte imbalance not corrected,Patients with increased intracranial pressure (relative)
Hyperkalemia,Severe renal impairment (oliguria or anuria),Severe metabolic alkalosis,Hypersensitivity to any component,Patients with known glucose-6-phosphate dehydrogenase deficiency (relative, due to potential for Heinz body formation)
Food interactions are not clinically relevant as the drug is administered intravenously. However, oral intake may affect electrolyte levels; therefore, dietary intake of potassium, sodium, and other electrolytes should be considered when monitoring therapy. Avoid concurrent use with phosphate-containing oral products without medical advice due to risk of hyperphosphatemia.
No known food interactions. However, monitor dietary intake of sodium, potassium, and chloride to avoid electrolyte imbalances.
Dextrose 5% and electrolytes (Isolyte P) are generally considered to have low teratogenic risk. Dextrose solutions are essential for maintaining maternal glucose levels; severe electrolyte imbalances may pose risks. No specific teratogenic effects have been reported from the components at therapeutic doses. Trimester-specific risks: First trimester: No known teratogenicity. Second and third trimesters: Use is safe when indicated, but avoid hyperglycemia which may be associated with fetal macrosomia or neonatal hypoglycemia.
Isolyte H in Dextrose 5% is a balanced electrolyte solution with multiple electrolytes and 5% dextrose. Teratogenic risk: minimal due to components being normal physiological constituents. However, maternal hyperglycemia from dextrose may increase fetal risks including macrosomia and congenital anomalies if glucose not controlled. First trimester: no direct teratogenicity, but dextrose-induced hyperglycemia may be associated with neural tube defects. Second/third trimester: risk of fetal hyperinsulinemia, macrosomia, neonatal hypoglycemia if maternal glucose elevated.
Dextrose and electrolytes are normal constituents of human milk. No specific data on M/P ratio; however, these components are not expected to accumulate or cause adverse effects in breastfed infants. Use during breastfeeding is considered safe when clinically indicated.
Components are normal constituents of human milk. No specific M/P ratio data; dextrose, sodium, potassium, magnesium, chloride, acetate, gluconate are expected to transfer minimally. Use is compatible with breastfeeding. Monitor infant for electrolyte balance only if maternal levels are abnormal.
Pregnancy induces increased plasma volume and renal blood flow, potentially increasing clearance of fluids and electrolytes. However, dosing of Isolyte P with Dextrose 5% is typically based on maintenance requirements and clinical status; standard dosing is generally appropriate but may require adjustments based on maternal volume status, electrolyte levels, and glucose tolerance. No specific pharmacokinetic changes necessitating routine dose alterations; monitor maternal response and adjust rate accordingly.
Pregnancy increases plasma volume and glomerular filtration rate; may require higher infusion rates to achieve desired electrolyte balance. Dextrose load may need adjustment to avoid maternal hyperglycemia, especially in gestational diabetes. No dose changes for electrolyte components themselves; monitor clinical response and serum levels.
ISOLYTE P with DEXTROSE 5% is a balanced maintenance fluid containing multiple electrolytes including potassium, magnesium, and phosphorus. It is designed for pediatric patients or those requiring maintenance fluids with lower sodium content. Monitor serum electrolytes frequently, especially in renal impairment. This solution provides 5% dextrose, representing ~170 kcal/L, which can help prevent ketosis. Do not use in patients with hyperkalemia, severe renal failure, or uncorrected metabolic alkalosis. Infuse via central line only if peripheral access is inadequate due to potential phlebitis.
ISOLYTE H IN DEXTROSE 5% is a hypertonic solution (approximately 554 m Osm/L) that provides free water, electrolytes, and calories. Use caution in patients with renal impairment or those at risk for fluid overload. Monitor serum sodium, potassium, chloride, and glucose levels during infusion. Do not administer if solution is discolored or contains particulate matter. Compatible with most IV lines but avoid adding other drugs without checking compatibility.
This fluid is given intravenously to maintain hydration and electrolyte balance.,It contains sugar (dextrose) to provide calories.,Inform your healthcare provider if you have diabetes, kidney problems, or heart disease.,Report any signs of infection at the injection site, such as redness, swelling, or pain.,Tell your doctor if you experience muscle weakness, irregular heartbeat, or tingling sensations.,This medication may affect blood sugar levels; monitor if diabetic.
This solution is given through a vein to provide fluids, electrolytes, and sugar.,Tell your healthcare provider if you have kidney problems, heart issues, or if you are on a low-sodium or low-potassium diet.,Report any signs of fluid overload such as swelling, shortness of breath, or rapid weight gain.,You may need blood tests to check your body's electrolyte levels and blood sugar.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by ISOLYTE P with 5% Dextrose provides electrolyte replacement and caloric supplementation. Dextrose is metabolized to carbon dioxide and water, yielding energy. Electrolytes are essential for maintaining osmotic balance, acid-base equilibrium, and normal cellular function.. ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte H in Dextrose 5% provides a balanced electrolyte solution with glucose to maintain fluid and electrolyte homeostasis. Dextrose is metabolized to carbon dioxide and water, providing calories. Electrolytes replenish losses and maintain acid-base balance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion. Adult dose: 1000-2000 m L over 24 hours, adjusted based on fluid and electrolyte needs. Typical rate: 125-150 m L/hour.. The standard adult dose of ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; rate determined by clinical condition, electrolyte requirements, and fluid balance. Typical adult maintenance: 100-200 m L/hour. Maximum infusion rate: 1000 m L/hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Dextrose 5% and electrolytes (Isolyte P) are generally considered to have low teratogenic risk. Dextrose solutions are essential for maintaining maternal glucose levels; severe ele. ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Isolyte H in Dextrose 5% is a balanced electrolyte solution with multiple electrolytes and 5% dextrose. Teratogenic risk: minimal due to components being normal physiological const. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.